BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
May 6, 2025 • 10min
Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
Emmanuel Savioz, Chairman & CEO of Tigen Pharma, dives into the revolutionary world of decentralized CAR-T manufacturing. He outlines how producing therapies closer to treatment sites enhances patient care. The discussion includes a cutting-edge armored-CAR program with Memorial Sloan Kettering, showcasing Tigen's innovative non-viral platform for combating blood cancers like NHL and multiple myeloma. Savioz emphasizes automation and AI's role in streamlining production, positioning Tigen at the forefront of an evolving pharmaceutical landscape.
May 6, 2025 • 10min
Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria
CEO Klaus Dugi describes why the company is focused on mitochondria and how it using small molecules to fix them. He covers the three main disease areas Vandria is focused on, including a clinical program in mild cognitive impairment.
May 6, 2025 • 11min
Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance
Co-Founder & CEO Marc Gitzinger describes the success factors behind the IPO and walks us through the company's two lead programs. Plus, his thoughts on the evolving business model for this field.
May 5, 2025 • 8min
Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens
CEO Franz-Werner Haas describes the rationale for developing vaccines for the antimicrobial space, he explains the company's E. coli based platform, and he walks us through the pipeline.
May 5, 2025 • 9min
Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers
CEO Marina Udier describes the vaccine's design, what was presented at AACR, and discussions the company has had with U.S. FDA about running a registrational study. Plus, previewing upcoming data later this year in metastatic colorectal cancer.
May 5, 2025 • 13min
Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025
He describes the clinical multi-specific T-cell engager program that will have data this year, and highlights the idea behind a next-generation logic-gating platform. Plus, entering the clinic with a DLL3 radio-DARPin and choosing mesothelin as a second target.
May 4, 2025 • 8min
At a reception on the eve of Swiss Biotech Day, Swiss Biotech Association CEO Michael Altorfer introduces us to the conference and shares his thoughts on the state of biotech and global collaboration
He describes the goals of Swiss Biotech Day, explains how the Swiss biotech sector is funded more by private investment than perhaps other geographies, and discusses current events.
May 2, 2025 • 24min
Biotech investor Thilo Schroeder of Nextech Invest shares his take on biotech and discusses portfolio companies Revolution Medicines, Tubulis, and Circle Pharma
He describes the history of Nextech, including being an early investor in Blueprint Medicines and Peloton, and discusses the importance of investing in companies that have a wide moat to protect from today's fierce global competition.
May 2, 2025 • 12min
VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.
Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the BiTAC AND-gating platform the company uses to improve on the precision of T-cell engagers and antibody-drug conjugates.
May 1, 2025 • 15min
Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries
Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe.
